|
|
||||||||
ORIGINAL RESEARCH |
From the Laboratory of Perinatal Medicine and Molecular Biology, 2nd Institute of Obstetrics and Gynecology, and Department of Internal Medicine, University "La Sapienza," Rome, Italy.
Address reprint requests to: Emanuela Marinoni, MD 2nd Institute of Obstetrics and Gynecology University "La Sapienza" Viale Regina Elena, 324 I-00161 Rome Italy E-mail: perinat{at}flashnet.it
| Abstract |
|---|
|
|
|---|
Methods: We measured immunoreactive adrenomedullin in amniotic fluid collected by amniocentesis from 36 women with clinical diagnosis of preterm labor or preterm premature rupture of membranes (PROM) and from 18 normal pregnant women.
Results: Amniotic fluid from cases of PROM and failure to respond to tocolysis were associated significantly with higher amniotic fluid adrenomedullin concentrations (177.0 ± 22.5 pg/mL and 182.7 ± 22.0 pg/mL, respectively, P < .01) than that from uncomplicated pregnancies (101.2 ± 28.1 pg/mL) or preterm labor responsive to tocolysis (102.3 ± 26.8 pg/mL).
Conclusion: Amniotic fluid adrenomedullin is higher than normal in cases of PROM and preterm labor unresponsive to tocolysis, perhaps indicating enhanced synthesis from placenta or fetal membranes being stimulated by bacterial products.
Adrenomedullin is a novel peptide, widely distributed in human tissues and circulating in plasma, that influences control of systemic and local circulation and humoral secretion.1,2 It has been reported that cultured vascular smooth-muscle cells contain adrenomedullin mRNA and that endothelial cells produce adrenomedullin, which acts on specific receptors, eliciting long-lasting vasodilation through synthesis of cyclic AMP.3 Immunocytochemistry studies showed that adrenomedullin is distributed widely and modulates hormonal secretion.4 Adrenomedullin inhibits the secretion of ACTH, aldosterone, and insulin, and its secretion is stimulated by thyroid hormones, progesterone, and dexamethasone.5
We reported high concentrations of adrenomedullin in maternal and umbilical cord plasma, and in amniotic fluid, in term human pregnancies. The immunoreactive peptide was also in the placenta and fetal membranes,6 suggesting potential influence of the peptide during gestation. Epithelial cells of fetal membranes express adrenomedullin mRNA, and immunoreactive adrenomedullin was detected in amniotic fluid midgestation,7 suggesting that placental adrenomedullin might regulate hormonal and peptide secretion by placenta and fetal membranes. Recent studies found that adrenomedullin might modulate vascular tone as a paracrine regulator through the inhibition or stimulation of vasoactive agents, such as nitric oxide8 and endothelin,9 both of which are produced by human placenta and fetal membranes and involved in the control of myometrial contractility.10,11 We hypothesize that adrenomedullin, directly through the cyclic AMP or indirectly through the regulation of nitric oxide and endothelin or other modulators (eg, corticotrophin releasing hormone, and prostaglandins) could also affect uterine contractility.
To determine whether placental adrenomedullin secretion was increased in association with preterm labor, we measured its concentration in amniotic fluid. Because adrenomedullin acts as a local mediator in an autocrine-paracrine manner,12 amniotic fluid adrenomedullin, more than maternal plasma, might better indicate its production from placental tissues.
| Material and Methods |
|---|
|
|
|---|
Preterm labor was defined as regular uterine contractions, at least two every 10 minutes over a period of at least 60 minutes, and cervical dilatation at least 2 cm. Women with cervical dilatation greater than 4 cm were not included because betamethasone was given immediately after admission and amniocentesis was not done. None of the subjects had clinical evidence of infection at the time of sampling, and all amniocentesis were done within 24 hours from admission (mean 11 ± 6 hours).
Women with PROM who were included did not have preterm labor at the time of sampling, although they all received prophylactic oral ritrodine, 10 mg twice daily (Miolene, Lusofarmaco S.p.a., Milan, Italy), but no antibiotic. Women with preterm labor received intravenous ritrodine infusion (8001200 mg daily) at the time of admission. On the basis of fetal lung maturity tests, 20 women received betamethasone for stimulation of fetal lung maturity, but amniocentesis was done before administration of glucocorticoids.
Women with preterm labor were categorized according to their response to tocolysis; 17 responded and contractions stopped for at least 7 days, whereas ten had dilation progress beyond 5 cm and delivered within a few days (range 16 days). One women delivered at ± days after sampling, by cesarean without labor; she was included in the responder group because contractions stopped after tocolysis until cesarean was done. Clinical and demographic characteristics are shown in Table 1
. This study was approved by the local ethics committee and informed consent was obtained from all participants.
|
-atrial natriuretic peptide. The intra- and interassay coefficients of variance were 5.1% and 12.0%, respectively. All tissues were evaluated carefully at the time of delivery for histologic evidence of chorionamnionitis, defined as the presence of infiltration of the chorioamnion with polymorphonuclear white blood cells. Analysis of the data was done both including and excluding women who had histologic evidence of infection.
Data were expressed as mean values ± standard deviation (SD). Statistical analysis was done with determination of Spearman rank-order correlation, and comparison between groups was done by pairwise multiple-comparison test (Student-Newman-Keuls test) because data were normally distributed. Fisher exact test was used to compare proportions between groups. Statistical significance was set at P < .05.
| Results |
|---|
|
|
|---|
| Discussion |
|---|
|
|
|---|
| Footnotes |
|---|
Received August 5, 1998. Received in revised form November 12, 1998. Accepted December 3, 1998.
| References |
|---|
|
|
|---|
2. Ichiki Y, Kitamura K, Kangawa K, Kamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 1994;338:610.[Medline]
3. Ishizaka Y, Ishizaka Y, Tanaka M, Kitamura K, Kangawa K, Minamino N, et al. Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994;200:6426.[Medline]
4. Samson WK, Murphy T, Schell DA. A novel vasoactive peptide, adrenomedullin, inhibits pituitary adrenocorticotropin release. Endocrinology 1995;136:234952.[Abstract]
5. Minamino N, Shoji H, Sugo S, Kangawa K, Matsuo H. Adrenocortical steroids, thyroid hormones and retinoic acid augment the production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;211:68693.[Medline]
6. Marinoni E, Di Iorio R, Letizia C, Villaccio B, Scucchi L, Cosmi EV. Immunoreactive adrenomedullin in human fetoplacental tissues. Am J Obstet Gynecol 1998;179:7847.[Medline]
7. Macri CJ, Martinez A, Moody TW, Gray KD, Miller MJ, Gallagher M, et al. Detection of adrenomedullin, a hypotensive peptide, in amniotic fluid and fetal membranes. Am J Obstet Gynecol 1996; 175:90611.[Medline]
8. Miura K, Ebara T, Okumura M, Matsuura T, Kim S, Yukimura T, et al. Attenuation of adrenomedullin-induced renal vasodilatation by NG-nitro L-arginine but not glibenclamide. Br J Pharmacol 1995;115:91724.[Medline]
9. Kohno M, Kano H, Horio T, Yokokawa K, Yasunari K, Takeda T. Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. Hypertension 1995;25:118590.
10. Izumi H, Yallampalli C, Garfield RE. Gestational changes in L-arginine-induced relaxation of pregnant rat and human myometrial smooth muscle. Am J Obstet Gynecol 1993;169:132737.[Medline]
11. Word RA, Kamm KE, Casey ML. Contractile effect of prostaglandins, oxytocin, and endothelin-1 in human myometrium in vitro: Refractoriness of myometrial tissue of pregnant women to prostaglandins E2 and F2 alpha. J Clin Endocrinol Metab 1992;75:102732.[Abstract]
12. Seguchi H, Mishimura N, Kobayashi S, Kumazawa J, Kanaide H. Autocrine regulation of the renal arterial tone by adrenomedullin. Biochem Biophys Res Commun 1995;215:61925.[Medline]
13. Grose C, Meehan T, Weiner CP. Prenatal diagnosis of congenital cytomegalovirus infection by virus isolation after amniocentesis. Pediatr Infect Dis J 1992;11:6057.[Medline]
14. Letizia C, Cerci S, Centanni M, De Toma G, Subioli S, Scuro L, et al. Circulating levels of adrenomedullin in patients with Addisons disease before and after corticosteroid treatment. Clin Endocrinol 1998;48:203.
15. Upton PD, Austin C, Taylor GM, Nandha A, Clark AJ, Ghatei MA, et al. Expression of adrenomedullin (ADM) and its binding sites in the rat uterus: Increased number of binding sites and ADM messenger ribonucleic acid in 20-day pregnant rats compared with nonpregnant rats. Endocrinology 1997;138:250814.
16. Romero R, Avila C, Brekus CA, Morotti R. The role of systemic and intrauterine infection in preterm parturition. Ann N Y Acad Sci 1991;622:35575.[Medline]
17. Romero R, Brody DT, Oyarzun E, Mazor M, Wu YK, Hobbins JC, et al. Infection and labor. III. Interleukin-1: A signal for the onset of parturition. Am J Obstet Gynecol 1989;160:111723.[Medline]
18. Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, et al. Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;207:2532.[Medline]
19. Hirata Y, Mitaka C, Sato K, Nagura T, Tsunoda Y, Amaha K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 1996;81:144953.[Abstract]
20. Challis JRG, Gibb W. Control of parturition. Prenat Neonatal Med 1996;1:28391.
This article has been cited by other articles:
![]() |
E. Marinoni, C. Zacharopoulou, A. Di Rocco, C. Letizia, M. Moscarini, and R. Di Iorio Effect of Betamethasone In Vivo on Placental Adrenomedullin in Human Pregnancy Reproductive Sciences, September 1, 2006; 13(6): 418 - 424. [Abstract] [PDF] |
||||
![]() |
T. Moriyama, T. Otani, and T. Maruo Expression of Adrenomedullin by Human Placental Cytotrophoblasts and Choriocarcinoma JAr Cells J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3958 - 3961. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |